Why the study?
Does the DEMOB protocol (without radiation) improve outcomes and prevent neurotoxicity in a pediatric patient with multifocal primary brain lymphoma?
Does the DEMOB protocol (without radiation) improve outcomes and prevent neurotoxicity in a pediatric patient with multifocal primary brain lymphoma?
The DEMOB chemotherapy protocol without radiation successfully treated a pediatric primary brain lymphoma without causing neurotoxicity.
May support radiation-free DEMOB in pediatric brain lymphoma; hypothesis-generating, requires prospective validation before practice change.
A 3.5-year-old boy with a multifocal primary lymphoma of the brain was treated successfully without neurotoxicity with a treatment regimen that did not include radiation. The protocol of Dexacort (dexamethasone), methotrexate, Oncovin (vincristine), and BCNU (carmustine) (DEMOB), which was developed with the use of MTX pharmacokinetic studies, was given over 7.5 months, and resulted in tumor disappearance on computerized tomography scans and marked improvement in clinical status. The patient remains in good health 3 years after diagnosis (March 1985).
No takes yet. Share an insight, caveat, or question.
Cohen et al. (1986) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: